Justine M. Anderson, MD

Hematology, Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Penn Presbyterian
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

My education and training

  • Medical School: New York Medical College
  • Residency: Icahn School of Medicine at Mount Sinai
  • Fellowship: Icahn School of Medicine at Mount Sinai

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Anderson is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Petrone G, Handa S, Anderson J, Chowdhury N, Kwon D, Jain P, Bhardwaj AS, Smith CB, Berger N. “Examining Inpatient Chemotherapy Utilization Among Patients with Cancer and Impact on Outcomes” , Oncologist , 30(11): 2025,oyaf214.


Vargas Pivato de Almeida D, Anderson J, Danila D, Morris M, Slovin S, Abida W, Cohn E, Baser R, Scher H, Autio K. “Evaluating Immune-Related Adverse Events Using Patient-Reported Outcomes in a Phase II Study of Ipilimumab in Patients with Hormone-Sensitive Prostate Cancer” , Journal of Immunotherapy and Precision Oncology, 6(4): 2023,162-169


Shyu M, Golec S, Anderson J, Linker AS, Nguyen VT, Raucher B, Dunn A. Analysing Monday discharges to identify lost opportunities for weekend discharge. , Intern Med J , 53(4): 2023,625-628


Autio K, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP, Dittamore R, Schreiber NA, Summa JM, Youssoufian H, Morris MJ, Scher HI. “Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer” , JAMA Oncology, 4(10): 2018,1344-1351